4 Results for "

MYPT1 phosphorylation

" in MedChemExpress (MCE) Product Catalog:
Products (4)

4 Results for "MYPT1 phosphorylation" in MCE Product Catalog:

Cat. No.: HY-156397
Purity:  99.42%
Target:  

AMPK YAP

Research Areas:  

Cancer

HTH-02-006 is a NUAK2 inhibitor, with an IC50 value of 126 nM. HTH-02-006 inhibits NUAK2-mediated signaling by reducing phosphorylation of its substrate MYPT1 at S445 and downstream MLC. HTH-02-006 shows growth inhibitory efficacy in YAP-high cancer cells (HuCCT-1, SNU475). HTH-02-006 significantly suppresses YAP-induced hepatomegaly (reduced liver/body weight ratio) in TetO-YAP S127A transgenic mice and demonstrates significant anti-tumor efficacy in mice bearing HMVP2 prostate cancer allografts. HTH-02-006 can be used for the study of liver cancer and prostate cancer .
loading...
    loading...
Cat. No.: HY-110335A
CAS No.: 944955-32-2
Target:  

ROCK

Research Areas:  

Cancer

OXA-06 is a pharmacologic inhibitor of ROCK, possessing antitumor activity by impairing cell migration and MYPT1 phosphorylation in PANC-1 cells.
loading...
    loading...
Cat. No.: HY-189132
CAS No.: 5459-61-0
Target:  

ROCK

Research Areas:  

Cardiovascular Disease

NSC-2488 hydrochloride is a ROCK-II inhibitor with an IC50 of 8.02 nM. NSC-2488 hydrochloride inhibits ROCK-II enzyme activity, blocks MYPT1 phosphorylation, and induces vascular smooth muscle relaxation. NSC-2488 hydrochloride can be used for research on hypertension .
loading...
    loading...
Cat. No.: HY-182361
CAS No.: 3097515-05-1
Target:  

AMPK JAK Cadherin

Research Areas:  

Cancer

NUAK1-IN-3 is a potent and selective NUAK1 inhibitor with an IC50 of 0.49 nM. NUAK1-IN-3 also inhibits NUAK2 and JAK3 with IC50 values of 265 and 225 nM. NUAK1-IN-3 engages Glu139 of NUAK1, forms a salt bridge between its bicyclic ring nitrogen and Asp142, and uses a fluorine atom to enhance hydrophobic binding interactions. NUAK1-IN-3 attenuates MYPT1 phosphorylation, suppresses the NUAK1-MYPT1 signaling axis, and inhibits proliferation, migration, and invasion of triple-negative breast cancer cells. NUAK1-IN-3 reverses TGF-β1-induced epithelial-mesenchymal transition (EMT) marker alterations, downregulates Snail and N-cadherin, and upregulates E-cadherin in tumor tissues. NUAK1-IN-3 suppresses tumor growth in triple-negative breast cancer xenograft models. NUAK1-IN-3 can be used for the research of triple-negative breast cancer .
loading...
    loading...